FIELD: medicine.
SUBSTANCE: invention relates to immunology and medicine. Disclosed are biomarkers for predicting the development of tumours in hepatocellular carcinoma and other types of cancer, measuring biomarkers for prescribing an anti-cancer immunotherapy agent targeted against ICOS+ regulatory T-cells, for example, selecting patients for treatment with an anti-ICOS antibody. Biomarkers provide (i) the ratio of the number of double-positive ICOS and FOXP3 cells located within a certain radius of influence around single-positive ICOS cells to the total number of single-positive ICOS cells, (ii) average distance between each ICOS-positive FOXP3-negative cell and the closest to it double-positive by ICOS and FOXP3 cell, (iii) fraction of FOXP3-positive cells, which is ICOS-positive cells, and (iv) density of ICOS-positive cells.
EFFECT: invention promotes prediction of clinical course of disease and therapy in patients.
16 cl, 15 dwg, 4 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES TO ICOS | 2016 |
|
RU2742241C2 |
| VECTOR, CO-EXPRESSING MOLECULES FOR VACCINATION AND COSTIMULATORY MOLECULES | 2016 |
|
RU2714157C2 |
| ANTI-HLA-A2 ANTIBODIES AND THEIR APPLICATION METHODS | 2018 |
|
RU2782276C2 |
| MONOCLONAL ANTIBODY SUPPRESSING THE IMMUNOSUPPRESSIVE FUNCTIONS OF PATHOGENS, ANTIGEN-BINDING FRAGMENT OF THE SPECIFIED ANTIBODY AND HYBRIDOMAS PRODUCING THE SPECIFIED ANTIBODY | 2017 |
|
RU2751918C2 |
| ANTIBODY AGAINST TNFR2 AND ITS APPLICATION | 2020 |
|
RU2793165C1 |
| FUSION PROTEIN COMPRISING IL-2 PROTEIN AND CD80 PROTEIN AND ITS USE | 2019 |
|
RU2811541C2 |
| NEW CHIMERIC ANTIGEN RECEPTOR CONSTRUCTS CONTAINING TNFR2 DOMAINS | 2019 |
|
RU2808254C2 |
| PROTEINS BASED ON ANTIBODY WITH GRAFTED CYTOKINE AND METHODS FOR THEIR USE IN IMMUNE DISORDERS | 2018 |
|
RU2786730C2 |
| ANTI-TRBC1 ANTIGEN-BINDING DOMAIN | 2018 |
|
RU2791327C2 |
| NOVEL MOLECULES OF AGONISTIC ANTI-TNFR2 ANTIBODIES | 2019 |
|
RU2840049C2 |
